Alexander C Schmidt

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi Bovine parainfluenza virus type 3 (BPIV3) fusion and hemagglutinin-neuraminidase glycoproteins make an important contribution to the restricted replication of BPIV3 in primates
    A C Schmidt
    Laboratory of Infectious Disease, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Virol 74:8922-9. 2000
  2. ncbi Recombinant bovine/human parainfluenza virus type 3 (B/HPIV3) expressing the respiratory syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3
    A C Schmidt
    Laboratory of Infectious Disease, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Virol 75:4594-603. 2001
  3. ncbi Mucosal immunization of rhesus monkeys against respiratory syncytial virus subgroups A and B and human parainfluenza virus type 3 by using a live cDNA-derived vaccine based on a host range-attenuated bovine parainfluenza virus type 3 vector backbone
    Alexander C Schmidt
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Virol 76:1089-99. 2002
  4. ncbi A novel human parainfluenza virus type 1 (HPIV1) with separated P and C genes is useful for generating C gene mutants for evaluation as live-attenuated virus vaccine candidates
    Emmalene J Bartlett
    Laboratory of Infectious Diseases, RNA Viruses Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892 2007, USA
    Vaccine 28:767-79. 2010
  5. ncbi Human parainfluenza virus type 2 V protein inhibits interferon production and signaling and is required for replication in non-human primates
    Anne Schaap-Nutt
    Laboratory of Infectious Diseases, RNA Viruses Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892, USA
    Virology 397:285-98. 2010
  6. ncbi Identification of human parainfluenza virus type 2 (HPIV-2) V protein amino acid residues that reduce binding of V to MDA5 and attenuate HPIV-2 replication in nonhuman primates
    Anne Schaap-Nutt
    LID, NIAID, NIH, 50 South Drive, Room 6511, MSC 8007, Bethesda, MD 20892, USA
    J Virol 85:4007-19. 2011
  7. ncbi Determinants of the host range restriction of replication of bovine parainfluenza virus type 3 in rhesus monkeys are polygenic
    Mario H Skiadopoulos
    Respiratory Viruses Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Virol 77:1141-8. 2003
  8. ncbi Human parainfluenza virus type 1 C proteins are nonessential proteins that inhibit the host interferon and apoptotic responses and are required for efficient replication in nonhuman primates
    Emmalene J Bartlett
    Laboratory of Infectious Diseases, Respiratory Viruses Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, U S Department of Health and Human Services, Bethesda, Maryland 20892 8007, USA
    J Virol 82:8965-77. 2008
  9. ncbi Human parainfluenza virus serotypes differ in their kinetics of replication and cytokine secretion in human tracheobronchial airway epithelium
    Anne Schaap-Nutt
    Laboratory of Infectious Diseases, RNA Viruses Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 2007, USA
    Virology 433:320-8. 2012
  10. ncbi The C proteins of human parainfluenza virus type 1 block IFN signaling by binding and retaining Stat1 in perinuclear aggregates at the late endosome
    Henrick Schomacker
    RNA Viruses Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America
    PLoS ONE 7:e28382. 2012

Detail Information

Publications21

  1. ncbi Bovine parainfluenza virus type 3 (BPIV3) fusion and hemagglutinin-neuraminidase glycoproteins make an important contribution to the restricted replication of BPIV3 in primates
    A C Schmidt
    Laboratory of Infectious Disease, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Virol 74:8922-9. 2000
    ..The usefulness of rBPIV3-F(H)HN(H) as a vaccine candidate against HPIV3 and as a vector for other viral antigens is discussed...
  2. ncbi Recombinant bovine/human parainfluenza virus type 3 (B/HPIV3) expressing the respiratory syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3
    A C Schmidt
    Laboratory of Infectious Disease, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Virol 75:4594-603. 2001
    ....
  3. ncbi Mucosal immunization of rhesus monkeys against respiratory syncytial virus subgroups A and B and human parainfluenza virus type 3 by using a live cDNA-derived vaccine based on a host range-attenuated bovine parainfluenza virus type 3 vector backbone
    Alexander C Schmidt
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Virol 76:1089-99. 2002
    ....
  4. ncbi A novel human parainfluenza virus type 1 (HPIV1) with separated P and C genes is useful for generating C gene mutants for evaluation as live-attenuated virus vaccine candidates
    Emmalene J Bartlett
    Laboratory of Infectious Diseases, RNA Viruses Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892 2007, USA
    Vaccine 28:767-79. 2010
    ..rHPIV1-C(Delta 84-85)+P will be investigated as a potential live-attenuated vaccine candidate for HPIV1...
  5. ncbi Human parainfluenza virus type 2 V protein inhibits interferon production and signaling and is required for replication in non-human primates
    Anne Schaap-Nutt
    Laboratory of Infectious Diseases, RNA Viruses Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892, USA
    Virology 397:285-98. 2010
    ....
  6. ncbi Identification of human parainfluenza virus type 2 (HPIV-2) V protein amino acid residues that reduce binding of V to MDA5 and attenuate HPIV-2 replication in nonhuman primates
    Anne Schaap-Nutt
    LID, NIAID, NIH, 50 South Drive, Room 6511, MSC 8007, Bethesda, MD 20892, USA
    J Virol 85:4007-19. 2011
    ..Using a transient expression system, 20 additional mutant V proteins were screened for MDA5 binding, and the region spanning residues 175 to 180 was found to be essential for this activity...
  7. ncbi Determinants of the host range restriction of replication of bovine parainfluenza virus type 3 in rhesus monkeys are polygenic
    Mario H Skiadopoulos
    Respiratory Viruses Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Virol 77:1141-8. 2003
    ....
  8. ncbi Human parainfluenza virus type 1 C proteins are nonessential proteins that inhibit the host interferon and apoptotic responses and are required for efficient replication in nonhuman primates
    Emmalene J Bartlett
    Laboratory of Infectious Diseases, Respiratory Viruses Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, U S Department of Health and Human Services, Bethesda, Maryland 20892 8007, USA
    J Virol 82:8965-77. 2008
    ..Thus, the C proteins of HPIV1 are nonessential but have anti-IFN and antiapoptosis activities required for virulence in primates...
  9. ncbi Human parainfluenza virus serotypes differ in their kinetics of replication and cytokine secretion in human tracheobronchial airway epithelium
    Anne Schaap-Nutt
    Laboratory of Infectious Diseases, RNA Viruses Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 2007, USA
    Virology 433:320-8. 2012
    ..The T cell chemoattractants CXCL10 and CXCL11 were the most abundant chemokines induced. Differences in replication and cytokine secretion might explain some of the differences in PIV serotype-specific pathogenesis and epidemiology...
  10. ncbi The C proteins of human parainfluenza virus type 1 block IFN signaling by binding and retaining Stat1 in perinuclear aggregates at the late endosome
    Henrick Schomacker
    RNA Viruses Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America
    PLoS ONE 7:e28382. 2012
    ..The F170S mutation in HPIV1 C did not prevent perinuclear co-localization with Stat1, but apparently weakened this interaction such that, upon IFN stimulation, Stat1 was translocated to the nucleus to induce an antiviral response...
  11. ncbi Progress in the development of human parainfluenza virus vaccines
    Alexander C Schmidt
    RNA Viruses Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Expert Rev Respir Med 5:515-26. 2011
    ..Vaccines against HPIV1 and HPIV2 are less advanced and have just entered pediatric trials...
  12. ncbi Growth restriction of an experimental live attenuated human parainfluenza virus type 2 vaccine in human ciliated airway epithelium in vitro parallels attenuation in African green monkeys
    Anne Schaap-Nutt
    Laboratory of Infectious Diseases, RNA Viruses Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892 2007, USA
    Vaccine 28:2788-98. 2010
    ..This restriction paralleled attenuation in the upper and lower respiratory tract of African green monkeys, supporting the HAE model as an appropriate and convenient system for characterizing HPIV2 vaccine candidates...
  13. ncbi The C proteins of human parainfluenza virus type 1 (HPIV1) control the transcription of a broad array of cellular genes that would otherwise respond to HPIV1 infection
    Jim B Boonyaratanakornkit
    Laboratory of Infectious Diseases, Respiratory Viruses Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland 20892 8007, USA
    J Virol 83:1892-910. 2009
    ..Thus, changes in host cell transcription did not reflect the striking phenotypic differences observed between these two viruses...
  14. ncbi More antibody with less antigen: can immunogenicity of attenuated live virus vaccines be improved?
    Alexander Bukreyev
    Respiratory Viruses Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 50 South Drive, Room 6517, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 99:16987-91. 2002
    ..Thus, it might be possible to develop live-attenuated vaccines that are as immunogenic as parental WT virus or, possibly, even more so...
  15. ncbi Recombinant human parainfluenza virus type 2 with mutations in V that permit cellular interferon signaling are not attenuated in non-human primates
    Anne Schaap-Nutt
    Laboratory of Infectious Diseases, RNA Viruses Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892, USA
    Virology 406:65-79. 2010
    ..This indicates that loss of HPIV2's ability to inhibit IFN signaling is insufficient to attenuate virus replication in vivo as long as IFN induction is still inhibited...
  16. ncbi Pathogenesis of acute respiratory illness caused by human parainfluenza viruses
    Henrick Schomacker
    Laboratory of Infectious Diseases, RNA Viruses Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, Bethesda, MD, USA
    Curr Opin Virol 2:294-9. 2012
    ..Studies using ex vivo human airway epithelium have focused on virus tropism, cellular pathology and the epithelial inflammatory response, elucidating how events early in infection shape the adaptive immune response and disease outcome...
  17. ncbi Role of interferon in the replication of human parainfluenza virus type 1 wild type and mutant viruses in human ciliated airway epithelium
    Emmalene J Bartlett
    Laboratory of Infectious Diseases, Respiratory Viruses Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland 20892 2007, USA
    J Virol 82:8059-70. 2008
    ....
  18. ncbi Progress in respiratory virus vaccine development
    Alexander C Schmidt
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 10001, USA
    Semin Respir Crit Care Med 32:527-40. 2011
    ..This review aims to provide a brief update on investigational vaccines against RSV, the PIVs, and MPV that have been evaluated in clinical trials or are currently in clinical development...
  19. ncbi Progress in respiratory virus vaccine development
    Alexander C Schmidt
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892 8007, USA
    Semin Respir Crit Care Med 28:243-52. 2007
    ..Reverse genetics systems that allow rational vaccine development are now widely used, and considerable progress has been made in preclinical and clinical development of novel respiratory virus vaccines...
  20. ncbi Respiratory syncytial virus and other pneumoviruses: a review of the international symposium--RSV 2003
    Alexander C Schmidt
    Department of Pediatric Pulmonology and Immunology, Charite University Hospital, Berlin, Germany
    Virus Res 106:1-13. 2004
    ..Chanock Award for lifetime achievement in RSV research, an award named in honor of the person who started the field of RSV research by recovering the first human RS virus from infants with severe bronchiolitis in 1956...
  21. ncbi In silico identification of a putative new paramyxovirus related to the Henipavirus genus
    Henrick Schomacker
    Department of Pediatrics, Charite University Hospital, Berlin, 13353, Germany
    Virology 330:178-85. 2004
    ..Given the highly pathogenic nature of the henipaviruses, the origin of these sequences is enigmatic, and attempts to identify and isolate HNLV are warranted...